Leland Stanford Junior University

California Institute of Technology

Alvine Pharmaceuticals, Inc.

Celiac Sprue Research Foundation

Michael Thomas Bethune

David Baltimore

Chaitan Khosla

Kenan Christopher Garcia

Juan Luis Mendoza

Jonathan David Gass

Michael Edward Birnbaum

Lu Shan

Gary Gray

Gail G Pyle

Matthew John Siegel

Indu Isaacs

Gregg Strohmeier

Marvin H Gee

Jocelyn T Kim

Guideng Li

Stephanie Wong

Alok V Joglekar

Michael T Leonard

Described herein are compositions and methods for signaling and antigen-presenting bifunctional receptors (SABRs) comprising one or more antigen presenting domains; and one or more signal transduction domains, wherein the one or more antigen presenting domains comprise a binding fragment of a major histocompatibility complex (MHC) molecule. Various immunological functions of the SABRs are also described.

Signaling and antigen-presenting bifunctional receptors (SABR)

Disclosed herein are trogocytosis based TCR ligand discovery platforms and methods of using the same, trogocytosis based TCR discovery platforms and methods of using the same, and trogocytosis based ligand discovery platforms and methods of using the same. Also disclosed herein are isolated cells, nucleotides, sequences, and sequence databases produced using trogocytosis based discovery platforms.

Trogocytosis mediated epitope discovery methods

Compositions and methods are provided for the identification of peptide sequences that are ligands for a T cell receptor (TCR) of interest, in a given MHC context.

Ligand discovery for T cell receptors

Disclosed herein are genetically engineered T cell receptors, and methods, vectors, and genetically engineered T cells related to genetically engineered T cell receptors.

Domain-swap T cell receptors

Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.

Enzyme treatment of foodstuffs for celiac sprue

A combination enzyme product consisting of a glutamine specific endoprotease and a prolyl endopeptidase is provided. Both enzymes are active and stable in the stomach and can therefore be administered as lyophilized powders or simple capsules/tablets. A ratio of the two enzymes is used to maximize their synergy.

Combination enzyme therapy for digestion of dietary gluten

The response of a patient with an enteropathic disease to therapy, particularly a candidate therapy in a clinical trial setting, is assessed by detecting the ability of the patient to metabolize an orally administered CYP3A substrate. The CYP3A metabolism may be monitored in a variety of ways. Conveniently, the appearance of a metabolite of the CYP3A substrate is detected in a patient sample over a period of time following oral administration, e.g. in urine, plasma, breath, saliva, etc. The CYP3A substrate is optionally labeled, e.g. with an isotopic, fluorescent, etc. label.

Biomarker to measure drug efficacy in enteropathic disease

Pharmaceutical formulations of glutenase enzymes are provided. The enzymes find particular use in the treatment of a Celiac or dermatitis herpetiformis patient.

Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis

Enzyme treatment of foodstuffs for Celiac Sprue

Growing community of inventors

Pasadena, CA, United States of America

Michael Thomas Bethune